Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care

Rhea-AI Summary

Onco-Innovations (OTCQB:ONNVF) chaired Colorectal Cancer Canada’s fourth Catalysts roundtable, Beyond Borders: Data-Driven Innovation for Global Precision Oncology, held virtually on December 2, 2025. The invitation-only session gathered ~20 senior leaders from industry, government, academic medicine, and clinical programs to discuss national scalability, data governance, interoperability, and transportable evidence for precision oncology.

Speakers included leaders from BC Cancer, University of Calgary, Inka Health, and others. Next steps: an internal roundtable report, a 2026 manuscript integrating series insights, advocacy materials on data innovation, and formation of working groups to advance AI-enabled precision medicine.

Key Figures

Roundtable session number: Fourth session Participants: Approximately 20 senior leaders Session duration: Two-and-a-half-hour session +2 more

5 metrics

Roundtable session number Fourth session Colorectal Cancer Canada Catalysts series

Participants Approximately 20 senior leaders Invitation-only virtual roundtable on December 2, 2025

Session duration Two-and-a-half-hour session Precision oncology roundtable discussions

Series duration goal Compress a decade into five years Colorectal Cancer Canada oncology progress ambition

Publication year 2026 manuscript Planned manuscript integrating insights across the Catalysts series

Market Reality Check

Price: $1.10 Vol: Volume 4,000 vs 20-day av...

high vol

$1.10 Last Close

Volume Volume 4,000 vs 20-day average 1,396 (relative volume 2.86), indicating elevated trading interest pre-news. high

Technical Price at 1.19 is trading below the 200-day MA of 1.45, showing a longer-term downtrend despite the recent rise.

Peers on Argus

No peers with momentum or same-day headlines were identified, so the 8.18% pre-n...

No peers with momentum or same-day headlines were identified, so the 8.18% pre-news gain and higher volume appear stock-specific rather than part of a broader sector move.

Historical Context

5 past events · Latest: Aug 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Aug 13	Private placement close	Negative	-7.7%	Closing of non-brokered private placement raising capital via units and warrants.
Aug 04	Clinical trial prep	Positive	-7.7%	Start-up agreement to prepare regulatory and clinical documents for first-in-human trial.
Jul 30	AI project win	Positive	-7.7%	Inka Health chosen to lead AI oncology project using real-world data for ECAs.
Jul 29	Private placement	Negative	-7.7%	Announced non-brokered private placement and new equity incentives for funding needs.
Jul 11	AI collaboration	Positive	-7.7%	Services agreement with Redwood AI to enhance PNKP inhibitor development via AI tools.

Pattern Detected

Recent positive operational and AI/clinical milestones often saw negative price reactions, while financing-related news aligned with downside moves, suggesting a tendency to sell into strength.

Recent Company History

Over the last few months, Onco-Innovations reported multiple developments, including AI-focused collaborations and steps toward a first-in-human trial for its PNKP inhibitor (Jul 11, Jul 30, Aug 4). It also announced and then closed a non-brokered private placement of $400,000 on Jul 29 and Aug 13. Those events generally saw -7.69% reactions, even for seemingly positive clinical and AI news. Today’s forum leadership announcement fits the ongoing narrative of building an oncology data and precision-medicine ecosystem.

Market Pulse Summary

This announcement highlights Onco-Innovations’ leadership in shaping data-driven precision oncology ...

Analysis

This announcement highlights Onco-Innovations’ leadership in shaping data-driven precision oncology infrastructure. By chairing a high-level roundtable with about 20 senior stakeholders, the company extends prior AI and clinical initiatives into policy, data governance, and real-world research domains. Historically, the company has combined AI collaborations and early-stage clinical planning with equity financings. Investors may watch for concrete follow-on outputs, such as the planned 2026 manuscript and formation of working groups.

Key Terms

precision oncology, transportable evidence, causal inference, synthetic data, +4 more

8 terms

precision oncology medical

"Beyond Borders: Data-Driven Innovation for Global Precision Oncology"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

transportable evidence technical

"the importance of transportable evidence and causal inference for global clinical adoption"

Transportable evidence is clinical or real‑world data gathered in one location, patient group, or healthcare setting that regulators, payers, or companies can reasonably use to support decisions in another location or population. Investors care because it can shorten development time, lower costs and broaden market access—think of it like a well‑documented recipe that can be trusted to work in multiple kitchens, reducing the risk and expense of proving the same results again.

causal inference technical

"the importance of transportable evidence and causal inference for global clinical adoption"

Causal inference is the process of figuring out whether one action or event actually produces a change in another, rather than just happening alongside it. For investors this matters because it helps separate real drivers of revenue, risk or performance from coincidences, so decisions (like allocating capital or valuing a strategy) are based on likely effects, not misleading patterns — like proving watering makes plants grow rather than assuming wetter soil and taller plants are unrelated.

synthetic data technical

"new data sources, including patient support program information and synthetic data, in real-world"

Data that is artificially generated to mimic the patterns and structure of real-world information without exposing actual personal or proprietary records. Investors care because synthetic data can let companies develop, test and demonstrate products faster and with lower privacy and regulatory risk—like using a realistic flight simulator instead of flying a real plane—while also carrying risks if the fake data fails to capture important real-world quirks.

real-world oncology research medical

"synthetic data, in real-world oncology research."

Real-world oncology research uses information gathered from everyday clinical care—such as electronic health records, insurance claims, patient registries, and doctor notes—to study how cancer treatments perform outside tightly controlled clinical trials. For investors, it matters because these findings reveal how well a therapy works for broader, more diverse patients, how often it’s used, and what costs or safety issues emerge in routine practice, helping predict market uptake, reimbursement and long-term value.

data governance technical

"through the lens of national scalability, data governance, interoperability, and the practical"

Data governance is the set of rules and practices that ensure information is accurate, consistent, and used responsibly within an organization. It is like a well-organized library system that keeps track of all the books, making sure they are correct, easy to find, and used properly. For investors, strong data governance helps ensure that the information they rely on is trustworthy and decisions are based on reliable data.

interoperability technical

"through the lens of national scalability, data governance, interoperability, and the practical"

Interoperability is the ability of different systems, devices, or software to work together smoothly and share information easily. It matters to investors because it enables more efficient operations, better data sharing, and faster decision-making across various platforms or technologies. When systems are interoperable, they can connect and communicate as if they were part of a single, unified system, reducing complexity and increasing overall effectiveness.

AI-enabled precision medicine medical

"policy pathways required to advance AI-enabled precision medicine in Canada and globally."

AI-enabled precision medicine uses computer intelligence to analyze a patient’s biological, lifestyle and medical data to choose or design treatments that are more likely to work for that individual. For investors it signals potential for smaller, faster clinical trials, lower development costs and therapies that can command premium prices or capture niche markets — think of it as using smart maps to find the fastest route to an effective treatment.

AI-generated analysis. Not financial advice.

VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce, further to its news release dated September 12, 2025, the completion of the fourth session in Colorectal Cancer Canada's Catalysts: Innovating for Tomorrow Series, led by its subsidiary, Inka Health Corp. ("Inka Health" or "Inka"). The invitation-only virtual roundtable, titled Beyond Borders: Data-Driven Innovation for Global Precision Oncology, held on December 2, 2025, brought together approximately 20 senior leaders from across the oncology ecosystem, including representatives from industry, government, academic medicine, and leading clinical programs, for a highly interactive and action-oriented discussion focused on accelerating national progress in precision oncology.

The roundtable, chaired by Dr. Paul Arora, Co-founder of Onco-Innovations' subsidiary Inka Health, featured opening remarks from Colorectal Cancer Canada (CCC) President and CEO Barry D. Stein, followed by framing insights from Series Chair Dr. Lilian Siu of the Princess Margaret Cancer Centre.

Throughout the two-and-a-half-hour session, participants engaged in a series of thematic discussions addressing critical enablers of next-generation cancer care. Presentations by Dr. Steven Jones of BC Cancer, Dr. Alind Gupta of Inka Health, and Dr. Winson Cheung of the University of Calgary explored the current state of precision medicine in Canada, the importance of transportable evidence and causal inference for global clinical adoption, and the growing role of new data sources, including patient support program information and synthetic data, in real-world oncology research. These topics were examined through the lens of national scalability, data governance, interoperability, and the practical frameworks required to translate technical advancements into routine clinical benefit.

The roundtable also featured structured breakout groups and a collaborative synthesis session designed to generate concrete actions that will inform an upcoming publication outlining CCC's vision for the future of cancer care in Canada. The high-level participation, which included leaders such as Michael Duong, Head of Innovations at Roche Canada, David Singletary, CEO of Subsalt, and Farah Husein, Director of Science and Methods at Canada's Drug Agency, reflects the growing recognition that precision oncology requires coordinated innovation across sectors, data systems, and jurisdictions.

"This fourth roundtable marks a pivotal moment as we are moving from vision to actionable roadmaps that will make precision oncology equitable and routine worldwide. Having the Onco-Innovations team lead this discussion helps orient the outcomes toward items that are practical, innovative, and patient centred," said Barry D. Stein, President and CEO of Colorectal Cancer Canada.

Colorectal Cancer Canada's Catalysts series continues to build on more than a decade of national roundtable initiatives and reflects a commitment to compressing a decade of oncology progress into five years. By leading this pivotal session, Onco-Innovations further strengthens its role in shaping the data infrastructures, partnerships, and policy pathways required to advance AI-enabled precision medicine in Canada and globally. Next steps include the development of an internal roundtable report, contributions to a 2026 manuscript integrating insights across the series, and the creation of new advocacy materials on data innovation for the national health system. The outcomes will also guide the formation of working groups and multidisciplinary teams to advance high-impact research, including public-private partnerships.

"Onco-Innovations was proud to chair this critical conversation because precision oncology must transcend borders. By harnessing transportable evidence, causal inference, and privacy-preserving data sources, we can deliver personalized care to every patient, regardless of geography or rarity of their cancer," stated Dr. Paul Arora, Co-Founder of Onco-Innovations subsidiary, Inka Health.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

About Inka Health

Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data, including genomics, transcriptomics, and proteomics, SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"

Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

What did Onco-Innovations (ONNVF) chair on December 2, 2025?

Onco-Innovations chaired Colorectal Cancer Canada’s roundtable titled Beyond Borders: Data-Driven Innovation for Global Precision Oncology on December 2, 2025.

Who participated in the ONNVF‑chaired precision oncology roundtable?

Approximately 20 senior leaders from industry, government, academic medicine, and clinical programs, including speakers from BC Cancer and University of Calgary.

What topics did the ONNVF session on precision oncology address?

The session focused on national scalability, data governance, interoperability, transportable evidence, causal inference, and new data sources for real‑world oncology research.

What are the next steps after the ONNVF‑led roundtable for precision oncology?

Planned next steps include an internal roundtable report, contributions to a 2026 manuscript, advocacy materials on data innovation, and new working groups for high‑impact research.

How does Onco-Innovations describe its role after chairing the CCC Catalysts session?

Onco-Innovations says chairing the session strengthens its role in shaping data infrastructures, partnerships, and policy pathways for AI‑enabled precision medicine in Canada and globally.